Genzyme 2004 Annual Report - Home About Genzyme Site Map Legal Disclaimer
Genzyme 2004 Annual Report
Genzyme Logo baby

Mona Sleiman, shown here at 13 months of age, was diagnosed with Pompe disease at 3 months old. Her family looks forward to the approval of Myozyme, Genzyme's therapy for treating this disorder. Myozyme is Genzyme's largest development program. Regulatory filings are underway in Europe and will soon follow in the United States and Japan.

fill room lyophilized meds
Table of Contents
2004 - A Transforming Year
Financial Highlights
Letter To Shareholders
A Future of Hope
Building a Sustainable Future
Focused Medical Areas
Genetic Diseases
Renal Disease
Orthopaedics
Oncology
Transplant / Immune Diseases
Genetics / Diagnostics
A Future of Innovation
A Future of Commitment
A Future of Growth
2004 - A Transforming Year

Genzyme had a great year in 2004, decisively confirming our strategy for long-term sustainability and consistent future growth. We achieved strong results across all of our businesses, allowing us to invest in new medical areas, such as oncology, while expanding our established areas of focus. We exceeded our goal by generating 31 percent non-GAAP earnings per share growth through a successful strategy based on:

  • Diversifying across a carefully selected set of medical areas, technologies, and products.

  • Using the infrastructure we have built in manufacturing, distribution, clinical and regulatory affairs, and sales and marketing to maximize business performance.

  • Expanding our global reach in sales, manufacturing, and research to benefit patients in all corners of the world.